Details

Autor(en) / Beteiligte

• Debrut, Léa
• Giannini, Margherita
• Klein, Delphine
• Spielmann, Lionel
• Mertz, Philippe
• Martin, Thierry
• Nadaj-Pakleza, Aleksandra
• Hirschi, Sandrine
• Nespola, Benoit
• Lannes, Béatrice
• Terzic, Joëlle
• Hinschberger, Olivier
• Dervieux, Benjamin
• Lipsker, Dan
• Arnaud, Laurent
• Gottenberg, Jacques-Eric
• Kleinmann, Jean François
• Geny, Bernard
• Séverac, François
• Velten, Michel
• Sibilia, Jean
• Meyer, Alain

Titel

Refining Incidence and Characteristics of Inflammatory Myopathies: A Quadruple-Source Capture-Recapture Survey Using the 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria

Ist Teil von

• Arthritis & rheumatology (Hoboken, N.J.), 2023-10, Vol.75 (10), p.1850-1855

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Inflammatory myopathies (IM), characterized by muscle inflammation and weakness, are rare systemic diseases. Our previous study estimated an IM incidence rate of 7.98 cases per million people per year (95% confidence interval 7.38-8.66) and highlighted important variations that were likely because of methodologic issues rather than true epidemiologic differences. In this study, we aimed to refine the incidence of IM, using the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for IM and a quadruple-source capture-recapture method during a 6-year period in Alsace, France, a region with a population of 2 million having benefits of good access to health care and accredited IM referral centers. Clinical data of potential IM patients were obtained from 4 sources (general practitioners and community specialists, public and private hospital records, public and private laboratories, and archives from the pathology department). Patients residing in Alsace and who fulfilled the 2017 EULAR/ACR criteria for IM between January 1, 2006, and January 1, 2013, were included. We corrected potentially incomplete ascertainment of cases with capture-recapture analyses. We studied both spatial and temporal distributions of incidence of IM. We also assessed systemic manifestations of the disease. Our review of 1,742 potential cases identified 106 patients with IM. No spatial or temporal heterogeneity was observed. Use of log-linear models showed an estimated 14.9 additional missed cases. Thus, the incidence rate of IM was 8.22 new cases per million inhabitants per year (95% confidence interval 6.76-9.69). Extramuscular manifestations other than dermatomyositis rash were frequently recorded. The stringent methodology used in our study provides an accurate estimation of the incidence of IM. This study also demonstrates, in a population-based cohort, the systemic nature of IM.